PARP inhibitors for breast cancer
Metastatic breast cancer
Lynparza and Talzenna are targeted therapies known as PARP inhibitors. Both agents have received FDA approval for treating metastatic breast cancer caused by a BRCA mutation. BRACAnalysis CDx—a companion diagnostic test—received approval at the same time as the agents. The National Comprehensive Cancer Network (NCCN) has added both agents as a preferred single agent treatment for people with advanced breast cancer and a BRCA mutation.
Breast cancer clinical trials
Research is now also looking at PARP inhibitor effectiveness in additional settings including:
- patients with
metastatic breast cancer who have other inherited mutations beyond BRCA1 and BRCA2, such as ATM and PALB2
- as adjuvant or neoadjuvant treatment for patients with earlier stage breast cancer
- patients with triple-negative
metastatic breast cancer
- PARP inhibitors in combination with other agents, such as drugs that shrink blood supply and immunotherapies.
You can look for research studies enrolling patients with breast cancer by visiting FORCE's Research Study Search Tool.
Updated 03/25/2019
